ALLO...$3...Hitting again...🥳
georgie18
Member Level
Re: None
Wednesday, October 30, 2024 10:54:12 AM
Post#
385056
of 385216
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
georgie18
Member Level
Re: None
Wednesday, October 30, 2024 10:54:12 AM
Post#
385056
of 385216
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
Recent ALLO News
- Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 • GlobeNewswire Inc. • 04/10/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:47:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 11:13:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:06:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 12:20:12 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:36:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:11:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:07:14 PM
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 03/12/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:42:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 02:04:36 AM
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update • GlobeNewswire Inc. • 03/02/2026 01:30:00 PM
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/05/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:20:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:09:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:07:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 10:16:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 10:16:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 10:15:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 09:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:15:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/22/2026 12:53:09 AM
- The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff • GlobeNewswire Inc. • 01/12/2026 03:14:09 PM
- Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T • GlobeNewswire Inc. • 01/08/2026 01:30:00 PM
- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis • GlobeNewswire Inc. • 12/15/2025 10:39:45 PM
